• / Free eNewsletters & Magazine
  • / My Account
Home>Drug Companies

Drug Companies

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals Inc. Investors and Encourages Investors to Contact the Firm

    Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals Inc. Investors and Encourages Investors to Contact the Firm

  2. Pharmaceutical Market Access Strategy for Ethiopia 2016 - Pharmaceutical Manufacturers , Pharmaceutical Distributors, Healthcare Providers, Contract Manufacturing Organisations - Research and Markets

    Pharmaceutical Market Access Strategy for Ethiopia 2016 - Pharmaceutical Manufacturers , Pharmaceutical Distributors, Healthcare Providers, Contract Manufacturing Organisations - Research and Markets

  3. Global Hepatitis B Pipeline Review H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Abivax, Akshaya Bio, GeneCure - Research and Markets

    Global Hepatitis B Pipeline Review H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Abivax, Akshaya Bio, GeneCure - Research and Markets

  4. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Pipeline Report 2016 - Global Review of 8 Companies & Drug Profiles - Research and Markets

    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Pipeline Report 2016 - Global Review of 8 Companies & Drug Profiles - Research and Markets

  5. Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)

    Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)

  6. UPDATE: 20 beaten-down U.S. stocks expected to rise as much as 98%

    UPDATE: 20 beaten-down U.S. stocks expected to rise as much as 98%

  7. KaloBios emerges from bankruptcy, with rights to a new rare disease treatment

    KaloBios emerges from bankruptcy, with rights to a new rare disease treatment

  8. AstraZeneca Licenses Drugs to LEO Pharma, Ends Valeant License

    AstraZeneca Licenses Drugs to LEO Pharma, Ends Valeant License

  9. Global Ventricular Tachycardia Pipeline Review 2016 Featuring Audentes Therapeutics, Gilead Sciences, HUYA Bioscience, Milestone Pharma & Perrigo Company - Research and Markets

    Global Ventricular Tachycardia Pipeline Review 2016 Featuring Audentes Therapeutics, Gilead Sciences, HUYA Bioscience, Milestone Pharma & Perrigo Company - Research and Markets

  10. Evotec and Ellersbrook Join Forces to Accelerate TargetNASH

    Evotec and Ellersbrook Join Forces to Accelerate TargetNASH

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.